Irhythm Holdings (IRTC) reported $747M in revenue for fiscal 2025, +26.2% year on year. That ranks #1965 by revenue among 2853 SEC filers and #185 in Healthcare. It posted a net loss of −$45.0M for the same year. Revenue has grown 31.4% a year on average since 2016 ($64.1M then). The fiscal 2025 balance sheet shows $1.0B in total assets, $236M in cash and $35.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $747M | +26.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $527M | +29.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$57.4M | +$58.1M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$45.0M | +$68.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $80.9M | +2,285.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $46.3M | +36.5% | FY20252025-12-31 |
| Total assetsAssets | $1.0B | +9.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $153M | +68.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $236M | −43.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $35.0M | +0.0% | FY20232023-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $199M | −$13.9M | Open → |
| Q2 20262026-06-30 | $224M | −$381,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Irhythm Holdings, Inc.
- Ticker
- IRTC
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001388658
Filings
- 10-QAug 6, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 19, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
| Emergent BiosolutionsEBS | $743M | $52.6M |
| RepligenRGEN | $738M | $48.9M |
| Pacira BiosciencesPCRX | $726M | $7.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Irhythm Holdings — Key figures |url=https://companiesranked.com/en/company/irhythm-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Irhythm Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/irhythm-holdingsBibTeX
@misc{companiesranked-en-company-irhythm-holdings-2026,
author = {{CompaniesRanked}},
title = {{Irhythm Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/irhythm-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001388658-26-000011 · February 19, 2026
{{cite web |title=Irhythm Holdings — Key figures — 10-K (0001388658-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1388658/000138865826000011/irtc-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-19}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.